Development of medicinal products for the treatment of post-traumatic stress disorder - Scientific guideline

This document provides guidance on the planning of clinical studies concerning the treatment of post-traumatic stress disorder.

Keywords: Post-traumatic stress disorder (PTSD), anxiety disorder

Current effective version

Guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)

Adopted Reference Number: CHMP/EWP/358650/2006 Corr 2* Legal effective date: 01/02/2009

English (EN) (71.16 KB - PDF)

Ippubblikat għall-ewwel darba: 24/07/2008 Aġġornata l-aħħar: 24/07/2008

Overview of comments received on draft guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)

Reference Number: EMEA/403001/2008 Corr*

English (EN) (147.56 KB - PDF)

Ippubblikat għall-ewwel darba: 24/07/2008 Aġġornata l-aħħar: 24/07/2008

Draft guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)

Draft: consultation closed Reference Number: CHMP/EWP/358650/06

English (EN) (61.08 KB - PDF)

Ippubblikat għall-ewwel darba: 20/09/2007 Aġġornata l-aħħar: 20/09/2007

Concept paper on the development of a guideline on the development of medicinal products for the treatment of post-traumatic stress disorder

Reference Number: EMEA/CHMP/EWP/358650/2006

English (EN) (65.09 KB - PDF)

Ippubblikat għall-ewwel darba: 21/09/2006 Aġġornata l-aħħar: 21/09/2006